PTAB To Scrutinize Xyrem Patents In Inter Partes Review
The Patent Trial and Appeal Board instituted inter partes review Tuesday of four Jazz Pharmaceuticals Inc. patents for the narcolepsy drug Xyrem, the same patents it previously refused to review under...To view the full article, register now.
Already a subscriber? Click here to view full article